Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics
GET POWR RATINGS... FREE!
MIRM Price/Volume Stats
| Current price | $26.13 | 52-week high | $30.55 |
| Prev. close | $26.07 | 52-week low | $17.32 |
| Day low | $25.22 | Volume | 568,000 |
| Day high | $26.44 | Avg. volume | 443,377 |
| 50-day MA | $25.50 | Dividend yield | N/A |
| 200-day MA | $22.71 | Market Cap | 993.78M |
MIRM Stock Price Chart Interactive Chart >
MIRM POWR Grades
- Momentum is the dimension where MIRM ranks best; there it ranks ahead of 78.35% of US stocks.
- MIRM's strongest trending metric is Growth; it's been moving up over the last 179 days.
- MIRM ranks lowest in Stability; there it ranks in the 9th percentile.
MIRM Stock Summary
- With a price/sales ratio of 10.66, MIRUM PHARMACEUTICALS INC has a higher such ratio than 90.21% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, MIRUM PHARMACEUTICALS INC is reporting a growth rate of 128.61%; that's higher than 89.6% of US stocks.
- As for revenue growth, note that MIRM's revenue has grown 199% over the past 12 months; that beats the revenue growth of 96.25% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to MIRUM PHARMACEUTICALS INC are API, ZLAB, VYNE, CYN, and PSNL.
- Visit MIRM's SEC page to see the company's official filings. To visit the company's web site, go to mirumpharma.com.
MIRM Valuation Summary
- In comparison to the median Healthcare stock, MIRM's price/sales ratio is 117.65% higher, now standing at 11.1.
- Over the past 47 months, MIRM's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for MIRM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MIRM | 2023-05-23 | 11.1 | 7.5 | -8.2 | -8.9 |
| MIRM | 2023-05-22 | 11.1 | 7.5 | -8.2 | -8.9 |
| MIRM | 2023-05-19 | 10.3 | 7.0 | -7.7 | -8.3 |
| MIRM | 2023-05-18 | 10.3 | 7.0 | -7.7 | -8.3 |
| MIRM | 2023-05-17 | 10.4 | 7.1 | -7.7 | -8.3 |
| MIRM | 2023-05-16 | 10.4 | 7.1 | -7.7 | -8.4 |
MIRM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MIRM has a Quality Grade of C, ranking ahead of 49.16% of graded US stocks.
- MIRM's asset turnover comes in at 0.052 -- ranking 319th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows MIRM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.052 | 1 | -0.949 |
| 2021-03-31 | 0.000 | NA | -1.229 |
| 2020-12-31 | 0.000 | NA | -1.146 |
| 2020-09-30 | 0.000 | NA | -0.934 |
| 2020-06-30 | 0.000 | NA | -0.781 |
| 2020-03-31 | 0.000 | NA | -0.694 |
MIRM Price Target
For more insight on analysts targets of MIRM, see our MIRM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $51.33 | Average Broker Recommendation | 1.29 (Strong Buy) |
Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
Latest MIRM News From Around the Web
Below are the latest news stories about MIRUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIRM as an investment opportunity.
Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual MeetingFOSTER CITY, Calif., May 19, 2023--Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting |
Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing CholangitisFOSTER CITY, Calif., May 18, 2023--Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis |
Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual MeetingFOSTER CITY, Calif., May 17, 2023--Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting |
Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia StudyFOSTER CITY, Calif., May 11, 2023--Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study |
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., May 11, 2023--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MIRM Price Returns
| 1-mo | -2.68% |
| 3-mo | 10.25% |
| 6-mo | 42.94% |
| 1-year | N/A |
| 3-year | 55.07% |
| 5-year | N/A |
| YTD | 34.00% |
| 2022 | 22.26% |
| 2021 | -8.65% |
| 2020 | -28.79% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...